Momordica charantia L., or bitter melon, has been suggested to exhibit anti-inflammatory activity. In a previous study, three structurally similar triterpenes, namely 5β, 5β, and 5β,, were isolated from bitter melon. EMCD has been shown to exhibit in vitro anti-inflammatory activity. In this study, the anti-inflammatory activities of EMCD, EMCO, and EDMO were compared. All three compounds were toxic to the RAW 264.7 macrophage cell line but not the FL83B cells. EMCD and EMCO inhibited tumor necrosis factorTNF)--induced inducible nitric oxide synthase (iNOS) expression in FL83B cells, and the IC 50 values were 19.8 and 25.7 M, respectively. By contrast, EDMO did not effectively reduce iNOS expression. Furthermore, EMCD and EMCO suppressed other TNF--induced proinflammatory signals including the activation of inhibitor kappa B kinase complex, the phosphorylation of inhibitor of nuclear factor-B, and the activation of c-Jun N-terminal kinase. EMCD consistently exhibited a higher efficacy than did EMCO in these assays. Hence, the in vivo anti-inflammatory activity of EMCD was tested. EMCD clearly repressed 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear edema in mice. In conclusion, differences in the functional group on carbon 19 do affect the anti-inflammatory activities of EMCD, EMCO, and EDMO. EMCD exhibited the highest anti-inflammatory activity among these molecules, and its in vivo anti-inflammatory activity was confirmed.
Inflammation is associated with several chronic disorders including type 2 diabetes, cancer, rheumatoid arthritis, and atherosclerosis. Momordica charantia L., also known as bitter melon, has been demonstrated to contain components with anti-inflammatory and hypoglycemic activities [1] [2] [3] [4] [5] [6] [7] . In a previous study, several hypoglycemic triterpenoids were identified in the extract of bitter melon fruits [2] . One of these molecules, 5β,19-epoxy-25-methoxycucurbita-6,23-diene-3β,19-diol (EMCD), has been revealed to exhibit in vitro anti-inflammatory activity [1] . EMCD was shown to suppress tumor necrosis factor(TNF)--induced expression of proinflammatory factors in the FL83B mouse hepatic line, including the expression of inducible nitric oxide synthase (iNOS), the p65 subunit of nuclear factor-B (NF-B), TNF-, and interleukin-1. Moreover, EMCD inhibited TNF--induced activation of the inhibitor kappa B kinase (IKK)/NF-B proinflammatory signaling pathway [1] . However, the in vivo antiinflammatory activity of EMCD has not been confirmed.
Two triterpenoids, which are structurally very similar to EMCD, were isolated with EMCD from bitter melon [2] . As shown in Figure 1 , the structures of 5β,19-epoxy-25-methoxycucurbita-6,23-dien-3β-ol (EMCO) and 5β,19-epoxy-19,25-dimethoxycucurbita-6,23-dien-3β-ol (EDMO) are nearly identical to that of EMCD, except for the functional groups on carbon 19. Compared with EMCD, EMCO lacks a hydroxyl group on carbon 19, whereas EDMO has a methoxy group instead of a hydroxyl group at this position. One can reasonably speculate that EMCO and EDMO may have activities similar to the activity of EMCD, and that these molecules may co-contribute to at least part of the antiinflammatory activity of bitter melon.
Whether EMCO and EDMO exhibit anti-inflammatory activities has not been ascertained. However, EDMO exhibited hypoglycemic activity, whereas EMCO did not [2] . Thus, the difference in functional groups on carbon 19 likely affects the activities of these three compounds. The aim of this study was to explore the structure-activity relationship of these three molecules in relation to their anti-inflammatory activities.
The lipopolysaccharide (LPS)-stimulated inflammatory response of the RAW 264.7 macrophage line is a commonly used cellular model for studying anti-inflammatory activity [8] [9] [10] [11] . Thus, the cytotoxic effects of the compounds were first examined in RAW 264.7 cells. Figure 2A displays that treatment with 20 to 40 M EMCO, EMCD, and EDMO clearly suppressed the survival of RAW 264.7 cells. By contrast, Figure 2B reveals that none of the three compounds were toxic to FL83B cells in the concentration range 20-40 M. These results reveal that the three molecules were not toxic to FL83B cells, a normal cell line, but were toxic to RAW 264.7 cells, a tumor and macrophage line. Whether the toxic effects on RAW264.7 cells were caused by an antitumor or antimacrophage activity or a combination of both requires further clarification.
To compare the anti-inflammatory activity of EMCD with the activities of EMCO and EDMO, TNF--stimulated FL83B cells were treated with different concentrations of the three compounds. Subsequently, iNOS expression was analyzed, and the IC 50 (the concentration of the compound required for achieving a 50% inhibition of iNOS expression) was determined for each compound. Figure 3A shows that iNOS expression was repressed by EMCD in a dose-dependent manner, and the IC 50 of EMCD was 19.8 M. The IC 50 of EMCO was 25.7 M ( Figure 3B) ; however, EDMO did not have an obvious effect on inhibiting iNOS expression, and its IC 50 could not be obtained using the concentrations tested (2-30 M; Figure 3C ). These data reveal that EMCD possessed the highest anti-inflammatory activity, followed by EMCO, whereas EDMO was the least effective. Hence, in conclusion, EDMO was not an efficient anti-inflammatory agent.
To further verify the distinction between the activities of EMCD and EMCO, their effects on other TNF--induced inflammatory markers were compared. Figure 4A shows that the TNF--induced phosphorylation of IKK was more evidently reduced by EMCD than by EMCO. The suppressive effect of EMCO at an equal concentration was less apparent. EMCD was consistently more effective in inhibiting the phosphorylation of the inhibitor of NF-B (IB) than was EMCO ( Figure 4B ). Figure 4C shows that both compounds suppressed the TNF--induced activation of c-Jun Nterminal kinase (JNK), a mitogen-activated protein kinase, whereas EMCD caused a more apparent reduction of phosphorylated JNK at lower concentrations. These results further support the conclusion that EMCD exhibited a higher anti-inflammatory activity than did EMCO.
Thus, the functional group on carbon 19 does affect the antiinflammatory activities of these molecules. The hydroxyl group at this position confers the highest anti-inflammatory activity on EMCD among the three compounds. In EDMO, the modification of -OH to -OCH 3 results in a larger group that probably interferes with the interaction between EDMO and its cellular target(s), thus leading to a loss of activity. By contrast, in EMCO, the substitution of -OH by -H confers a smaller group, reduces the hydrophilicity of the molecule, and possibly loses the formation of hydrogen bonds between this position and the cellular target(s). These reasons may explain the lower anti-inflammatory activity of EMCO than that of EMCD. Because EMCD exhibited the highest activity among the three compounds, its in vivo anti-inflammatory activity was tested in mice. The mice were divided into three groups, and 12-Otetradecanoylphorbol-13-acetate (TPA) was used to induce inflammation and edema on both ears of the mice; however, the left ears of the mice in the TPA control group were not stimulated by TPA. The right ears were treated with 500 g/ear indomethacin (an anti-inflammatory drug; positive control) or 300 g/ear EMCD or were not medicated (TPA control). For comparison, the left ears of all groups were not treated with an anti-inflammatory drug. As illustrated in Figure 5A , in the TPA control, ear edema was observed after 1 hour of TPA stimulation; it peaked at 6 to 18 hours, and remained obvious at 24 hours after TPA stimulation. In the indomethacin-treated group, reduction of inflammation was significant at 18 and 24 hours; in the EMCD-treated group, effective reduction in inflammation was observed at 6, 18, and 24 hours. Thus, the effect of 300 g/ear EMCD was similar to that of 500 g/ear indomethacin. Figure 5B presents the comparison between both ears of mice from the same group at 18 hours after TPA stimulation. In the TPA control, data confirmed that TPA stimulation caused obvious inflammation of the right ear compared with the unstimulated left ear. In the indomethacin-treated or EMCD-treated group, the inflammation at the right ear was apparently ameliorated by the medicine or compound compared with the nonmedicated left ear. Together, these data suggest that EMCD efficaciously reduced inflammation in vivo, and it is at least as efficient as that of indomethacin.
In conclusion, although the structures of EMCD, EMCO, and EDMO are extremely similar, their anti-inflammatory activities are distinct. The functional group present on carbon 19 does affect the activities of these molecules. In this study, EMCD exhibited the highest anti-inflammatory activity, and its anti-inflammatory effect in vivo was confirmed. Because EMCD exhibits both hypoglycemic and anti-inflammatory activities, it is a valuable natural compound present in bitter melon and merits further exploration.
Experimental
Natural product isolation: EMCD, EMCO, and EDMO were extracted from bitter melon, purified, and characterized in a previous study [2] . Briefly, dried fruit (30 kg) of bitter melon was extracted with methanol, followed by partitioning sequentially using ethyl acetate and n-butanol as solvents. The n-butanol fraction (966 g) was further processed by column chromatography using a Diaion HP-20 column, and eluted using mixtures of water and methanol of reducing polarity as eluents to result in 25 fractions. The constituents of fraction 16 (6.1 g) were further purified via chromatographies including a Sephadex LH-20 column, Si gel, and semipreparative HPLC to yield 5 compounds, including EMCD (36 mg), EMCO (87 mg), and EDMO (95 mg). The structures of these compounds were identified by comparing their physical and spectral data (IR, MS, and NMR) with the values reported in the literature. The purity of the compounds was more than 98%, as was confirmed by their 1 H-NMR spectra. These compounds were dissolved in DMSO (dimethylsulfoxide) to prepare stock solutions.
Other chemicals: Specific antibodies against phosphorylated IKKand IKK-, total IKK-, total IKK-, phosphorylated IB-, phosphorylated JNK, and total JNK were obtained from Cell Signaling Technology (Beverly, MA, USA); an iNOS antibody was obtained from BD Biosciences (Franklin Lakes, CA, USA); an actin antibody was obtained from Chemicon (Temecula, CA, USA). All secondary antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). TNF- was purchased from R&D Systems (Minneapolis, MN, USA). Fetal bovine serum was obtained from Invitrogen (San Diego, CA, USA). Cell culture media, indomethacin, TPA, DMSO, and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] were purchased from Sigma-Aldrich (St. Louis, MO, USA) and were of reagent grade or cell-culture grade.
Cell culture: RAW 264.7 cells and FL83B cells were purchased from the Bioresource Collection and Research Center (Hsinchu, Taiwan). They were cultured using the medium specified in the supplier's instructions at 37°C in a humidified incubator supplied with 5% CO 2 .
Cytotoxicity assay: RAW 264.7 or FL83B cells were cultured in 96-well plates. The cells were treated with the compounds at the specified concentrations in a serum-free medium for 16 hours, followed by MTT assays, as described previously [11] .
Western blot analysis:
The cells were seeded in 35-or 60-mm plates and washed with phosphate-buffered saline (PBS, pH 7.4); they were then treated with 20 ng/mL TNF-and the investigated compound at the specified concentration, or an equal volume of DMSO (control), in a serum-free medium for 3 hours or 10 min. The cells were then washed twice with PBS, subjected to cell lysis using a lysis buffer containing protease inhibitors (and phosphatase inhibitors for Figure 4 ), and centrifuged as described previously [1, 11] . The supernatant was collected, and the protein concentration was analyzed using a Bradford assay reagent (Bio-Rad, Hercules, CA, USA). Equal amounts of proteins were sampled and subjected to electrophoresis and Western blotting as described previously [1, 12] . Bands of chemiluminescence on the polyvinylidene difluoride membrane were detected using an imaging system (UVP Biospectrum, UVP, LLC, Upland, CA, USA). The intensities of the bands were analyzed using software provided with the system.
IC 50 determination:
The expression level of iNOS relative to the TNF--treated control (as 100% expression) was calculated using the band intensity of iNOS after normalization by that of actin. The experiments were performed independently thrice. Data were averaged and fitted, and the IC 50 values were calculated using the program SigmaPlot (Systat Software Inc., San Jose, CA, USA) according to the equation four-parameter logistic.
Animal tests: All animal test protocols were approved by the Committee for Animal Experiments of National Pingtung University of Science and Technology (Approval No. NPUST-IACUC-102-004). Mouse ear edema assay was performed as described previously [11] with modifications. Briefly, male ICR mice (25-30 g; purchased from BioLASCO, Taipei, Taiwan) were divided into three groups (six mice per group), namely TPA control, indomethacin, and EMCD groups. TPA (3 g/ear dissolved in 20 L of acetone) was topically applied to both ears of the mice in the indomethacin and EMCD groups; however, TPA was applied only to the right ears of the mice in the TPA control group, and 20 L of acetone was applied to the left ears of the mice in this group. After 1 hour, 300 g/ear EMCD dissolved in 20 L 50% DMSO and 50% acetone was applied to the right ear and 20 L of the solvent to the left ear in the EMCD group; 500 g/ear indomethacin dissolved in 20 L of acetone was applied to the right ear and 20 L of acetone to the left ear in the indomethacin group. In the TPA control group, 20 L 50% DMSO and 50% acetone was applied to both ears of the mice. The thickness of the ears was measured using a dial thickness gauge (Peacock, Ozaki, Tokyo, Japan) before and at 1, 6, 18, and 24 hours after TPA stimulation. All the mice were medicated with indomethacin after the completion of the experiments.
Statistical analysis: Data were analyzed using one-way analysis of variance followed by Scheffe's post hoc test. Significant difference was considered when P < 0.05 and F > 3.5546 versus the control.
